These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 37400647)

  • 41. Carbapenemase-producing uropathogens in real life: epidemiology and treatment at a County Emergency Hospital from Eastern Romania.
    Rusu A; Tiliscan C; Adamescu AI; Ganea OA; Arama V; Arama SS; Rascu SA; Jinga V
    J Med Life; 2023 May; 16(5):707-711. PubMed ID: 37520479
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mortality due to Multidrug-Resistant Gram-Negative Bacteremia in an Endemic Region: No Better than a Toss of a Coin.
    Tsachouridou O; Pilalas D; Nanoudis S; Antoniou A; Bakaimi I; Chrysanthidis T; Markakis K; Kassomenaki A; Mantzana P; Protonotariou E; Skoura L; Metallidis S
    Microorganisms; 2023 Jun; 11(7):. PubMed ID: 37512883
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antimicrobial Solutions for Endotracheal Tubes in Prevention of Ventilator-Associated Pneumonia.
    Marcut L; Manescu Paltanea V; Antoniac A; Paltanea G; Robu A; Mohan AG; Grosu E; Corneschi I; Bodog AD
    Materials (Basel); 2023 Jul; 16(14):. PubMed ID: 37512308
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Screening for Metallo-Beta-Lactamases Using Non-Carbapenem Agents: Effective Detection of MBL-Producing
    Takei K; Kanamori H; Nakayama A; Chiba M; Takei Y; Seike I; Kitamura C; Baba H; Oshima K; Tokuda K
    Antibiotics (Basel); 2023 Jul; 12(7):. PubMed ID: 37508242
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ca-EDTA restores the activity of ceftazidime-avibactam or aztreonam against carbapenemase-producing
    Wannigama DL; Sithu Shein AM; Hurst C; Monk PN; Hongsing P; Phattharapornjaroen P; Fox Ditcham WG; Ounjai P; Saethang T; Chantaravisoot N; Wapeesittipan P; Luk-In S; Sae-Joo S; Nilgate S; Rirerm U; Tanasatitchai C; Kueakulpattana N; Laowansiri M; Liao T; Kupwiwat R; Rojanathanes R; Ngamwongsatit N; Tungsanga S; Leelahavanichkul A; Devanga Ragupathi NK; Badavath VN; Hosseini Rad SMA; Kanjanabuch T; Hirankarn N; Storer RJ; Cui L; Amarasiri M; Ishikawa H; Higgins PG; Stick SM; Kicic A; Chatsuwan T; Abe S
    iScience; 2023 Jul; 26(7):107215. PubMed ID: 37496674
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Carbapenem-Resistant
    Giannella M; Verardi S; Karas A; Abdel Hadi H; Dupont H; Soriano A; Santerre Henriksen A; Cooper A; Falcone M;
    Open Forum Infect Dis; 2023 Jul; 10(7):ofad329. PubMed ID: 37496600
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Imipenem and meropenem influence the Las/Rhl quorum-sensing systems in clinical isolates of Pseudomonas aeruginosa.
    Deshamukhya C; Das BJ; Paul D; Dhar Chanda D; Bhattacharjee A
    Lett Appl Microbiol; 2023 Aug; 76(8):. PubMed ID: 37496211
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Spectrum of Tigecycline-Induced Pancreatitis in Clinical Characteristics, Diagnosis, and Management.
    Pan J; Ye C; Zhou LZ; Li ZY; Wang J; He X; Chen SJ; Zhou GQ
    Int J Gen Med; 2023; 16():2971-2979. PubMed ID: 37465554
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High prevalence of colistin heteroresistance in specific species and lineages of Enterobacter cloacae complex derived from human clinical specimens.
    Fukuzawa S; Sato T; Aoki K; Yamamoto S; Ogasawara N; Nakajima C; Suzuki Y; Horiuchi M; Takahashi S; Yokota SI
    Ann Clin Microbiol Antimicrob; 2023 Jul; 22(1):60. PubMed ID: 37454128
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ceftolozane/tazobactam heteroresistance in cystic fibrosis-related
    Monogue ML; Sanders JM; Pybus CA; Kim J; Zhan X; Clark AE; Greenberg DE
    JAC Antimicrob Resist; 2023 Aug; 5(4):dlad083. PubMed ID: 37441352
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical outcomes of ceftolozane-tazobactam dosing in patients with sepsis undergoing renal replacement therapies.
    El Nekidy WS; Al Ali M; Abidi E; Ghazi IM; Attallah N; El Lababidi R; Hijazi F; Mallat J
    Clin Nephrol; 2023 Sep; 100(3):126-131. PubMed ID: 37439527
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antimicrobial susceptibility of Bacteroides fragilis group organisms in Hong Kong, 2020-2021.
    Fang H; Li X; Yan MK; Tong MK; Chow KH; Cheng VC; Ho PL
    Anaerobe; 2023 Aug; 82():102756. PubMed ID: 37429411
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance.
    Tait JR; Harper M; Cortés-Lara S; Rogers KE; López-Causapé C; Smallman TR; Lang Y; Lee WL; Zhou J; Bulitta JB; Nation RL; Boyce JD; Oliver A; Landersdorfer CB
    Antimicrob Agents Chemother; 2023 Aug; 67(8):e0041423. PubMed ID: 37428034
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ceftazidime/avibactam-induced severe neutropenia: A case report.
    Wu W; Lai Y; Lin Y; Li T
    Br J Clin Pharmacol; 2023 Oct; 89(10):3204-3208. PubMed ID: 37427878
    [TBL] [Abstract][Full Text] [Related]  

  • 55. First report of a carbapenemase OXA-48-producing
    Sevillano L; Herrera C; Valdes Á; de la Hoz Á; Cardeñoso L; Domingo D; Semiglia MA
    Access Microbiol; 2023; 5(6):. PubMed ID: 37424558
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Heteroresistance to cefepime-taniborbactam in metallo-β-lactamase-encoding Enterobacterales.
    Abbott C; Satola SW; Weiss DS
    Lancet Infect Dis; 2023 Aug; 23(8):e277-e278. PubMed ID: 37421967
    [No Abstract]   [Full Text] [Related]  

  • 57. Carriage of ESBL-producing Klebsiella pneumoniae and Escherichia coli among children in rural Ghana: a cross-sectional study.
    Akenten CW; Khan NA; Mbwana J; Krumkamp R; Fosu D; Paintsil EK; Boahen KG; Osei-Mensa J; Maiga-Ascofare O; May J; Obiri-Danso K; Phillips RO; Ofori LA; Dekker D
    Antimicrob Resist Infect Control; 2023 Jul; 12(1):60. PubMed ID: 37400910
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.
    Craig WA
    Clin Infect Dis; 1998 Jan; 26(1):1-10; quiz 11-2. PubMed ID: 9455502
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Do pre-burn center management algorithms work? Evaluation of pre-admission diagnosis and treatment adequacy of burn patients referred to a burn center.
    Tuncer HB; Akın M; Çakırca M; Erkılıç E; Yıldız HF; Yastı AÇ
    J Burn Care Res; 2024 Jan; 45(1):180-189. PubMed ID: 37527451
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of risk factors of prolonged mechanical ventilation in patients with severe burn injury.
    Xiao K; Chen WX; Li XJ
    Clin Respir J; 2023 Aug; 17(8):791-798. PubMed ID: 37519126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.